{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T22:31:32Z","timestamp":1767911492359,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,10,11]],"date-time":"2016-10-11T00:00:00Z","timestamp":1476144000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s00115-016-0225-7","type":"journal-article","created":{"date-parts":[[2016,10,11]],"date-time":"2016-10-11T07:39:29Z","timestamp":1476171569000},"page":"1300-1304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Progressive multifokale Leukenzephalopathie","Progressive multifocal leukoencephalopathy"],"prefix":"10.1007","volume":"87","author":[{"given":"C.","family":"Warnke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. P.","family":"Wattjes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.\u2011P.","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Stangel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,11]]},"reference":[{"key":"225_CR1","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0140-6736(71)91777-6","volume":"1","author":"BL Padgett","year":"1971","unstructured":"Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH (1971) Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1:1257\u20131260","journal-title":"Lancet"},{"key":"225_CR2","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/art.24966","volume":"60","author":"ES Molloy","year":"2009","unstructured":"Molloy ES, Calabrese LH (2009) Progressive multifocal leukoencephalopathy: A national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 60:3761\u20133765","journal-title":"Arthritis Rheum."},{"key":"225_CR3","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/archneurol.2010.161","volume":"67","author":"C Warnke","year":"2010","unstructured":"Warnke C, Menge T, Hartung HP et\u00a0al (2010) Natalizumab and progressive multifocal leukoencephalopathy: What are the causal factors and can it be avoided? Arch Neurol 67:923\u2013930","journal-title":"Arch. Neurol."},{"key":"225_CR4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2016.21","volume":"12","author":"A Winkelmann","year":"2016","unstructured":"Winkelmann A, Loebermann M, Reisinger EC, Hartung HP, Zettl UK (2016) Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol 12:217\u2013233","journal-title":"Nat Rev Neurol"},{"key":"225_CR5","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/CMR.05031-11","volume":"25","author":"MW Ferenczy","year":"2012","unstructured":"Ferenczy MW, Marshall LJ, Nelson CD et al (2012) Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 25:471\u2013506","journal-title":"Clin. Microbiol. Rev."},{"key":"225_CR6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/1352458510385834","volume":"17","author":"C Warnke","year":"2011","unstructured":"Warnke C, Smolianov V, Dehmel T et\u00a0al (2011) CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Mult Scler 17:151\u2013156","journal-title":"Mult. Scler."},{"key":"225_CR7","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamaneurol.2014.63","volume":"71","author":"EM Frohman","year":"2014","unstructured":"Frohman EM, Monaco MC, Remington G et\u00a0al (2014) JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol 71:596\u2013602","journal-title":"JAMA Neurol"},{"key":"225_CR8","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1128\/JVI.02565-14","volume":"89","author":"T Loy Van","year":"2015","unstructured":"Van Loy T, Thys K, Ryschkewitsch C et\u00a0al (2015) JC virus quasispecies analysis reveals a complex viral population underlying progressive multifocal leukoencephalopathy and supports viral dissemination via the hematogenous route. J\u00a0Virol 89:1340\u20131347","journal-title":"J. Virol."},{"key":"225_CR9","doi-asserted-by":"crossref","first-page":"e1000368","DOI":"10.1371\/journal.pgen.1000368","volume":"5","author":"SR Sunyaev","year":"2009","unstructured":"Sunyaev SR, Lugovskoy A, Simon K, Gorelik L (2009) Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). Plos Genet 5:e1000368","journal-title":"Plos Genet."},{"key":"225_CR10","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1093\/brain\/awr206","volume":"134","author":"L Aly","year":"2011","unstructured":"Aly L, Yousef S, Schippling S et al (2011) Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome. Brain 134:2687\u20132702","journal-title":"Brain"},{"key":"225_CR11","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/ana.24574","volume":"79","author":"I Jelcic","year":"2016","unstructured":"Jelcic I, Jelcic I, Kempf C et\u00a0al (2016) Mechanisms of immune escape in central nervous system infection with neurotropic JC virus variant. Ann Neurol 79:404\u2013418","journal-title":"Ann. Neurol."},{"key":"225_CR12","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.24153","volume":"76","author":"C Warnke","year":"2014","unstructured":"Warnke C, von Geldern G, Markwerth P et al (2014) Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76:792\u2013801","journal-title":"Ann. Neurol."},{"key":"225_CR13","doi-asserted-by":"crossref","first-page":"e1004084","DOI":"10.1371\/journal.ppat.1004084","volume":"10","author":"E Sundqvist","year":"2014","unstructured":"Sundqvist E, Buck D, Warnke C et\u00a0al (2014) JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants. PLOS Pathog 10:e1004084","journal-title":"PLOS Pathog."},{"key":"225_CR14","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","volume":"80","author":"JR Berger","year":"2013","unstructured":"Berger JR, Aksamit AJ, Clifford DB et\u00a0al (2013) PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section. Neurology 80:1430\u20131438","journal-title":"Neurology"},{"key":"225_CR15","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/ana.20431","volume":"57","author":"IJ Koralnik","year":"2005","unstructured":"Koralnik IJ, Wuthrich C, Dang X et\u00a0al (2005) JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol 57:576\u2013580","journal-title":"Ann. Neurol."},{"key":"225_CR16","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ana.23973","volume":"74","author":"S Schippling","year":"2013","unstructured":"Schippling S, Kempf C, Buchele F et al (2013) JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment. Ann Neurol 74:622\u2013626","journal-title":"Ann. Neurol."},{"key":"225_CR17","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s00415-014-7336-5","volume":"261","author":"MP Wattjes","year":"2014","unstructured":"Wattjes MP, Vennegoor A, Mostert J, van Oosten BW, Barkhof F, Killestein J (2014) Diagnosis of asymptomatic natalizumab-associated PML: Are we between a rock and a hard place? J Neurol 261:1139\u20131143","journal-title":"J. Neurol."},{"key":"225_CR18","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/ana.23676","volume":"72","author":"TA Yousry","year":"2012","unstructured":"Yousry TA, Pelletier D, Cadavid D et al (2012) Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 72:779\u2013787","journal-title":"Ann. Neurol."},{"key":"225_CR19","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrneurol.2015.157","volume":"11","author":"MP Wattjes","year":"2015","unstructured":"Wattjes MP, Rovira A, Miller D et al (2015) Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis \u2013 establishing disease prognosis and monitoring patients. Nat Rev Neurol 11:597\u2013606","journal-title":"Nat Rev Neurol"},{"key":"225_CR20","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acn3.114","volume":"1","author":"T Dong-Si","year":"2014","unstructured":"Dong-Si T, Richman S, Wattjes MP et al (2014) Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clin Transl Neurol 1:755\u2013764","journal-title":"Ann Clin Transl Neurol"},{"key":"225_CR21","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/jnnp-2014-308630","volume":"86","author":"MP Wattjes","year":"2015","unstructured":"Wattjes MP, Vennegoor A, Steenwijk MD et al (2015) MRI pattern in asymptomatic natalizumab-associated PML. J Neurol Neurosurg Psychiatr 86:793\u2013798","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"225_CR22","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1177\/1352458514556296","volume":"21","author":"C Warnke","year":"2015","unstructured":"Warnke C, Stettner M, Lehmensiek V et\u00a0al (2015) Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. Mult Scler 21:1036\u20131044","journal-title":"Mult. Scler."},{"key":"225_CR23","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.24153","volume":"76","author":"C Warnke","year":"2014","unstructured":"Warnke C, von Geldern G, Markwerth P et al (2014) The CSF JCV antibody index for diagnosis of natalizumab-associated PML. Ann Neurol 76:792\u2013801","journal-title":"Ann. Neurol."},{"key":"225_CR24","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1212\/WNL.0b013e31823b9b27","volume":"77","author":"J Kuhle","year":"2011","unstructured":"Kuhle J, Gosert R, Buhler R et al (2011) Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology 77:2010\u20132016","journal-title":"Neurology"},{"key":"225_CR25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/1756285615602832","volume":"8","author":"D Pavlovic","year":"2015","unstructured":"Pavlovic D, Patera AC, Nyberg F, Gerber M, Liu M, Progressive Multifocal Leukeoncephalopathy Consortium (2015) Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord 8:255\u2013273. doi: 10.1177\/1756285615602832","journal-title":"Ther Adv Neurol Disord"},{"key":"225_CR26","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1056\/NEJMc1304828","volume":"370","author":"PS Giacomini","year":"2014","unstructured":"Giacomini PS, Rozenberg A, Metz I et al (2014) Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med 370:486\u2013488","journal-title":"N. Engl. J. Med."},{"issue":"306","key":"225_CR27","doi-asserted-by":"publisher","first-page":"306ra150","DOI":"10.1126\/scitranslmed.aac8691","volume":"7","author":"I Jelcic","year":"2015","unstructured":"Jelcic I, Combaluzier B, Jelcic I et al (2015) Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy. Sci Transl Med 7(306):306ra150. doi: 10.1126\/scitranslmed.aac8691","journal-title":"Sci Transl Med"},{"key":"225_CR28","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/bmt.2010.221","volume":"46","author":"A Balduzzi","year":"2011","unstructured":"Balduzzi A, Lucchini G, Hirsch HH et al (2011) Polyomavirus JC-targeted T\u2011cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transplant 46:987\u2013992","journal-title":"Bone Marrow Transplant."},{"issue":"306","key":"225_CR29","doi-asserted-by":"publisher","first-page":"306ra151","DOI":"10.1126\/scitranslmed.aab1720","volume":"7","author":"U Ray","year":"2015","unstructured":"Ray U, Cinque P, Gerevini S et al (2015) JC polyomavirus mutants escape antibody-mediated neutralization. Sci Transl Med 7(306):306ra151. doi: 10.1126\/scitranslmed.aab1720","journal-title":"Sci Transl Med"},{"key":"225_CR30","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/cid\/ciu682","volume":"59","author":"M Sospedra","year":"2014","unstructured":"Sospedra M, Schippling S, Yousef S et\u00a0al (2014) Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1. Clin Infect Dis 59:1588\u20131592","journal-title":"Clin. Infect. Dis."},{"key":"225_CR31","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C et al (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:1870\u20131880","journal-title":"N. Engl. J. Med."},{"key":"225_CR32","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1136\/jnnp-2012-304332","volume":"84","author":"C Warnke","year":"2013","unstructured":"Warnke C, Ramanujam R, Plavina T et al (2013) Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatr 84:1199\u20131205","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"225_CR33","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","volume":"76","author":"T Plavina","year":"2014","unstructured":"Plavina T, Subramanyam M, Bloomgren G et al (2014) Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76:802\u2013812","journal-title":"Ann. Neurol."},{"key":"225_CR34","first-page":"11","volume":"1","author":"C Volz-Zang","year":"2016","unstructured":"Volz-Zang C, Keller-Stanislawski B (2016) Aktualisierte Empfehlungen zur Minimierung des Risikos einer PML unter Tysabri\u00ae-Behandlung. Bull Arzneimittelsicherheit Informationen BfArM PEI 1:11\u201320","journal-title":"Bull Arzneimittelsicherheit Informationen BfArM PEI"},{"key":"225_CR35","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1212\/WNL.0b013e3182a351fb","volume":"81","author":"N Schwab","year":"2013","unstructured":"Schwab N, Schneider-Hohendorf T, Posevitz V et al (2013) L\u2011Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 81:865\u2013871","journal-title":"Neurology"},{"key":"225_CR36","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1212\/WNL.0000000000002314","volume":"86","author":"LA Lieberman","year":"2016","unstructured":"Lieberman LA, Zeng W, Singh C et al (2016) CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R\u2011MS patients. Neurology 86:375\u2013381","journal-title":"Neurology"},{"key":"225_CR37","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/ana.24345","volume":"77","author":"LM Villar","year":"2015","unstructured":"Villar LM, Costa-Frossard L, Masterman T et al (2015) Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Ann Neurol 77:447\u2013457","journal-title":"Ann. Neurol."}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-016-0225-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-016-0225-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-016-0225-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T12:42:43Z","timestamp":1568464963000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-016-0225-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,11]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["225"],"URL":"https:\/\/doi.org\/10.1007\/s00115-016-0225-7","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,11]]}}}